Aclaris Therapeutics (ACRS) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.13
- EPS estimate
- −$0.13
- EPS surprise
- +2.18%
- Revenue surprise
- +29.44%
- Revenue
- $1.8M
- Revenue estimate
- $1.4M
- Reported
- Aug 7, 2025
Aclaris Therapeutics' most recent quarter in the table is Q2 2025, reported August 7, 2025. It posted a loss of $0.13 per share, matching the $0.13 estimate and a 2.18% beat by the source's measure. Revenue was $1.8 million, 29.44% above the $1.4 million estimate. Against Q2 2024, the loss narrowed from $0.15 per share, while revenue fell 35.7% from $2.8 million.
Every quarter in the table was a loss. The annual loss per share was $1.63 in 2021, $1.33 in 2022, $1.27 in 2023 and $1.51 in 2024. The widest quarterly loss was $1.01 in Q4 2024 and the narrowest $0.02 in Q4 2023. Revenue has been uneven, with large quarters of $19.0 million in Q3 2022 and $17.6 million in Q4 2023 among many near $2 million. Aclaris beat EPS estimates in 14 of the 20 quarters, and in six of the last eight.
The table has no quarter after Q2 2025. In earlier years, third-quarter results came between November 2 and November 8, and fourth-quarter results in the last week of February. The next quarter added here will show whether the loss stays near the $0.12 to $0.13 per share of the first half of 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 7, 2025 | −$0.13 | −$0.13 | +2.18% | $1.8M | SEC |
| Q1 2025 | May 8, 2025 | −$0.15 | −$0.12 | +21.16% | $1.5M | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.29 | −$1.01 | −252.28% | $9.2M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.01 | −$0.11 | −1829.82% | $4.3M | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.20 | −$0.15 | +26.72% | $2.8M | SEC |
| Q1 2024 | May 7, 2024 | −$0.29 | −$0.24 | +16.00% | $2.4M | SEC |
| Q4 2023 | Feb 27, 2024 | −$0.34 | −$0.02 | +94.19% | $17.6M | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.48 | −$0.41 | +14.55% | $9.3M | SEC |
| Q2 2023 | Aug 7, 2023 | −$0.45 | −$0.42 | +6.69% | $1.9M | SEC |
| Q1 2023 | May 8, 2023 | −$0.44 | −$0.42 | +3.87% | $2.5M | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.45 | −$0.41 | +7.93% | $7.8M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.39 | −$0.30 | +23.31% | $19.0M | SEC |
| Q2 2022 | Aug 3, 2022 | −$0.36 | −$0.31 | +13.48% | $1.5M | SEC |
| Q1 2022 | May 10, 2022 | −$0.39 | −$0.31 | +21.18% | $1.5M | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.37 | −$0.37 | −1.37% | $1.5M | SEC |
| Q3 2021 | Nov 2, 2021 | −$0.28 | −$0.35 | −24.25% | $1.7M | SEC |
| Q2 2021 | Aug 5, 2021 | −$0.28 | −$0.34 | −23.64% | $1.8M | SEC |
| Q1 2021 | May 7, 2021 | −$0.30 | −$0.57 | −87.50% | $1.8M | SEC |
| Q4 2020 | Feb 25, 2021 | −$0.31 | −$0.30 | +2.44% | $1.6M | SEC |
| Q3 2020 | Nov 4, 2020 | −$0.31 | −$0.25 | +20.00% | $1.4M | SEC |
Quarterly revenue
Frequently asked questions
When did Aclaris Therapeutics (ACRS) last report earnings?
Aclaris Therapeutics last reported on Aug 7, 2025, covering fiscal Q2 2025.
Did ACRS beat earnings estimates?
Yes. Aclaris Therapeutics reported EPS of −$0.13 for Q2 2025 against a −$0.13 estimate — a 2.18% beat.
How much revenue did ACRS report last quarter?
Aclaris Therapeutics reported $1.8M in revenue for Q2 2025, against a consensus estimate of $1.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.